Recent research highlights a trend of high discontinuation rates among patients using glucagon-like peptide-1 receptor agonists for Type 2 diabetes and weight loss.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Growing evidence points to inconsistent GLP-1 adherence: 6 notes
